Functional Constipation Clinical Trial
Official title:
The Assessment of Lactobacillus Reuteri Efficacy, Provided With Forlax, as Treatment of Incurable Constipation in Children 3-7 Years. Double Blind, Placebo-controlled, Randomized and Multicenter Trial
The most common cause of children chronic constipation is functional disorders. Functional
constipation is diagnosed after excluding organic causes of constipation (anatomical,
neurological, endocrinological) and identification of two symptoms defined by the Rome III
criteria. There could be low number of bowel movements (below three times a week), defecation
pain, fecal incontinence (once a week), stool consistency or occurrence of large diameter
stools. The treatment is change of diet, defecation training and application of laxatives.
The probiotics are defined as living microorganisms, which provided in a proper doses should
result in beneficial effect on a host health. The assessment of its characteristic is related
to strain of bacteria affiliation.
Taking into the consideration that patients with constipation may experience microflora
intestine disorders, using the probiotics can have the positive impact on process of treating
this disease. The additional reason for using the probiotics during the constipation
treatment is an influence of probiotics on movement of the alimentary canal.
In spite of proved effectiveness of some probiotics' strains further research are required,
because clinical significance is ambiguous and the effect is confirmed among patients with
short medical history. That's way the further analysis of probiotic Lactobacillus reuteri DSM
17938, which was successful treatment method of chronic constipation amongst children
(infants) should be performed.
The primary aim of the study is the assessment of Lactobacillus reuteri DSM 17938 efficacy,
provided with macrogol (Forlax), as treatment of constipation in 3-7 years old children. The
baseline of estimation is the frequency comparison of bowel movement in children belonging
into two groups: Lactobacillus reuteri treatment and placebo.
The secondary aim of the study is the assessment of frequency the additional symptoms
connected with defecation disorders: such as: number of pain episodes during defecation, the
intensity of pain, number of hard stools, number of fecal incontinence per week, number of
macrogol (Forlax) pockets used.
The investigators believe that constipation treatment (laxatives- macrogol) with
Lactobacillus reuteri has better efficacy that the same treatment without Lactobacillus
reuteri in 3-7 years old children with medical history of chronic constipation.
Status | Unknown status |
Enrollment | 128 |
Est. completion date | December 2012 |
Est. primary completion date | April 2012 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 3 Years to 7 Years |
Eligibility |
Inclusion Criteria: - Children 3-7 years old - Occurrence less than three bowel movement per week - Medical history from at least two months] - Ineffective laxative treatment at least two months - The parents approval for child participation in the study and for the treatment Exclusion Criteria: - Well-known, organic cause of constipation (i.e. hypothyroidism, Hirschprung disease, cystis fibrosis) - Anatomic defects of the alimentary canal - The surgery of the alimentary canal in the past - Treatment of antibiotics/probiotics during last two weeks before start of the study |
Country | Name | City | State |
---|---|---|---|
Poland | ChildrensMHIPoland | Warsaw |
Lead Sponsor | Collaborator |
---|---|
Children's Memorial Health Institute, Poland |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of bowel movement per week, without fecal incontinence | 12 weeks | ||
Secondary | The number of bowel movements per week | Other secondary items are: the number of pain episodes during defecation per week, the number of hard stools, the number of fecal incontinence per week, the number of patients who have to change amount of drug or use of enema. | 12 weeks | |
Secondary | The number of pain episodes during defecation per week, | 12 weeks | ||
Secondary | The number of hard stools | 12 weeks | ||
Secondary | The number of fecal incontinence per week | 12 weeks | ||
Secondary | The number of patients who have to change amount of drug | 12 weeks | ||
Secondary | The number of patients who have to change use of enema. | 12 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04506801 -
The Effect of Probiotics on Functional Constipation in the Elderly
|
N/A | |
Completed |
NCT04620161 -
A Proof of Concept Study of Pradigastat in Patients With Functional Constipation
|
Phase 2 | |
Active, not recruiting |
NCT02361749 -
Botulinum Toxin Injection Versus Anal Myectomy in Management of Idiopathic Constipation
|
Phase 4 | |
Completed |
NCT03054805 -
The Effect of Probiotics on Constipation, and Intestinal Microflora in Children With Functional Constipation
|
Phase 4 | |
Not yet recruiting |
NCT01913665 -
The Effect of Bifidobacterium Lactis and Inulin on Functional Constipation
|
N/A | |
Completed |
NCT01622972 -
Mode of Action of Moviprep
|
Phase 4 | |
Completed |
NCT01348152 -
Effect of TU-100 in Patients With Functional Constipation
|
Phase 2 | |
Completed |
NCT01212146 -
Probiotic-enriched Artichoke in Functional Constipation
|
N/A | |
Completed |
NCT04231162 -
Effect of an 8-week Bifidobacterium Lactis HN019 Supplementation on Functional Constipation
|
N/A | |
Not yet recruiting |
NCT03639142 -
Dried Plums (Prunes) vs. Polyethylene Glycol 4000 for Treatment of Functional Constipation in Children
|
Phase 3 | |
Recruiting |
NCT04918329 -
Functional Digestive Disorders Observatory
|
||
Completed |
NCT02592200 -
Effect of Lactobacillus Gasseri DSM 27123 on Functional Constipation in Healthy Women
|
N/A | |
Completed |
NCT03707002 -
Effect of scFOS on Increase in Stool Frequency in Constipated People
|
N/A | |
Recruiting |
NCT06083311 -
The Efficacy of a Probiotic for Functional Constipation (FC)
|
N/A | |
Completed |
NCT04110145 -
Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation
|
Phase 2 | |
Recruiting |
NCT06196073 -
Visceral Osteopathy in Functional Constipation
|
N/A | |
Completed |
NCT04026113 -
Linaclotide Safety and Efficacy in Pediatric Participants, 6 to 17 Years of Age, With Irritable Bowel Syndrome With Constipation (IBS-C) or Functional Constipation (FC)
|
Phase 3 | |
Completed |
NCT02359396 -
A Randomized, Open-label, Three-arm Study of MZRW on Tolerability, Exposure and Pharmacokinetics
|
Phase 1 | |
Completed |
NCT01847950 -
Effects of scFOS on Stool Frequency in People With Functionnal Constipation
|
N/A | |
Recruiting |
NCT01274793 -
Trial for Quantity-Effect Relationship of Acupuncture With Two-ways Regulation to Treat Functional Enteropathy
|
Phase 1 |